Judge allows sales of Momenta drug copy

Bloomberg News/File

Momenta gets revenue from generic Lovenox sold by partner Novartis AG’s Sandoz unit.

Shares of Momenta Pharmaceuticals Inc., a Cambridge company that owns patents on the blood-thinner Lovenox, fell after a court cleared the way for Watson Pharmaceuticals to sell a generic version of the drug. The US Court of Appeals for the Federal Circuit granted Watson partner Amphastar Pharmaceuticals a stay of an order that prevented sales. A US judge in Boston blocked sales of the drug copy, saying Momenta was likely to win a patent-infringement suit it had filed. The Federal Circuit said its order “does not represent a final decision’’ on the merits of the appeal.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of